Conference abstract
Retro-inverso peptide inhibitors of β-amyloid oligomer formation as a novel treatment for the progression of Alzheimerâ??s disease
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Inhibition of Aβ oligomer formation could have a major impact on clinical progression from mild cognitive impairment (MCI) to Alzheimerâ??s disease (AD). We are working on retro-inverso (RI) peptides and RI-peptides attached to the surface of nanoparticles as therapeutically useful inhibitors of early-stage Aβ aggregation. The inhibitor RI-OR2-TAT consists of the Aβ binding peptide RI OR2 (rGffvlkGr) attached to a retro-inverso version of the transit peptide â??TATâ?? to target the inhibitor into the brain. Fluorescein-RI OR2-TAT has been shown to cross the blood brain barrier (BBB) of APPswe/PS1Î?E9 transgenic mice and bind to β amyloid plaques. Moreover, daily peripheral injection of RI-OR2-TAT into these mice for 21 days resulted in a 25% reduction (p<0.01) of Aβ oligomer levels, a 32% reduction (p<0.0001) of amyloid plaque count, a 44% reduction (p<0.0001) in the numbers of activated microglial cells, and a 25% reduction (p<0.0001) in oxidative damage. Covalent attachment of RI OR2 TAT toliposomes, to produce peptide-inhibitor nanoparticles (PINPS), has resulted in a remarkably potent multivalent inhibitor that has several advantages over the free peptide for further development as a potential drug. These include biocompatibility, stealth properties (to avoid detection by the immune system) and the possibility of designing multi-ligand systems directed at more than one target. Various drug candidates aimed at inhibiting the formation of Aβ, or inducing the clearance of senile plaques from the brain, have failed in recent years. Our RI peptide and nanoparticle-based therapies are an alternative approach to more conventional drugs and could offer some hope for success in future human clinical trials.
Keywords
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalBrain Disorders & Therapy
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “David Allsop”
